Multiple OmniActive Health Technologies' ingredients — including Capsimax, CurcuWIN, Lutemax 2020 and OmniLean — were the subjects of six study presentations at this year's Experimental Biology conference.
"OmniActive is dedicated to expanding research on our portfolio of ingredients and furthering the breadth of science that supports the use of nutraceuticals for human health," said Jayant Deshpande, Ph.D., who is the chief technology officer of OmniActive Health Technologies.
The research presented on Capsimax continues to support its role in weight management with results indicating reduced appetite and improved body composition. Another groundbreaking study on CurcuWIN supports its efficacy in a healthy population for heart and circulatory health. OmniLean — OmniActive's newly launched metabolic synergizer — was the subject of a study showing that supplementation can benefit metabolic health through its ability to support healthy carbohydrate/insulin metabolism.
"OmniActive takes great pride in being a leader in scientifically-backed, innovative ingredients that have market sustainability," said Lynda Doyle, vice president of global marketing, OmniActive Health Technologies. "To have six studies selected for representation at EB reinforces the sound science and rigorous research that OmniActive has become known for."
Experimental Biology, which took place April 2-6 in San Diego, California, drew approximately 14,000 scientists and exhibitors.